Development of acid inhibition without hypergastrinemia

Development of acid inhibition without hypergastrinemia - Development of acid inhibition

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031632

Enrollment

Registered

2018-04-01

Start date

2018-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypergastrinemia

Interventions

VPZ 10mg/day LAF 10mg x 2/day PIR 25mg x 3/day VPZ 10mg/day plus LAF 10mg x 2/day VPZ 10mg/day plus PIR 25mg x 3/day VPZ 10mg/day plus LAF 10mg x 2/day plus PIR 25mg x 3/day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The H.pylori naive candidate without medication in recent one month

Exclusion criteria

Exclusion criteria: 1.The candidate with past history 2.The candidate with pregnancy or breast-feeding 3.Smoker 4.The candidate without allowance of Medical Docter

Design outcomes

Primary

Measure	Time frame
Intragastric pH	—

Countries

Japan

Contacts

Public ContactTakahiro Suzuki

Hamamatsu University School of Medicine First Department of Medicine

takahr99@hama-med.ac.jp053-435-2261

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026